|
1
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups; National
Cancer Institute of Canada Clinical Trials Group: Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galli R, Binda E, Orfanelli U, Cipelletti
B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi
A: Isolation and characterization of tumorigenic, stem-like neural
precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells - perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pils D, Horak P, Gleiss A, Sax C, Fabjani
G, Moebus VJ, Zielinski C, Reinthaller A, Zeillinger R and Krainer
M: Five genes from chromosomal band 8p22 are significantly
down-regulated in ovarian carcinoma: N33 and EFA6R have a potential
impact on overall survival. Cancer. 104:2417–2429. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pribill I, Speiser P, Leary J, Leodolter
S, Hacker NF, Friedlander ML, Birnbaum D, Zeillinger R and Krainer
M: High frequency of allelic imbalance at regions of chromosome arm
8p in ovarian carcinoma. Cancer Genet Cytogenet. 129:23–29. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ribeiro IP, Marques F, Caramelo F, Pereira
J, Patrício M, Prazeres H, Ferrão J, Julião MJ, Castelo-Branco M,
de Melo JB, et al: Genetic gains and losses in oral squamous cell
carcinoma: Impact on clinical management. Cell Oncol (Dordr).
37:29–39. 2014. View Article : Google Scholar
|
|
10
|
Voeghtly LM, Mamula K, Campbell JL,
Shriver CD and Ellsworth RE: Molecular alterations associated with
breast cancer mortality. PLoS One. 7:e468142012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wiklund F, Jonsson BA, Göransson I, Bergh
A and Grönberg H: Linkage analysis of prostate cancer
susceptibility: Confirmation of linkage at 8p22-23. Hum Genet.
112:414–418. 2003.PubMed/NCBI
|
|
12
|
Fan X, Zhang X, Shen J, Zhao H, Yu X, Chen
Y, Zhuang Z, Deng X, Feng H, Wang Y, et al: Decreased TUSC3
promotes pancreatic cancer proliferation, invasion and metastasis.
PLoS One. 11:e01490282016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang Z, Guo M, Zhang X, Yao L, Shen J, Ma
G, Liu L, Zhao L, Xie C, Liang H, et al: TUSC3 suppresses
glioblastoma development by inhibiting Akt signaling. Tumour Biol.
37:12039–12047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Inui M, Martello G and Piccolo S: MicroRNA
control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar :
|
|
16
|
Schickel R, Boyerinas B, Park SM and Peter
ME: MicroRNAs: Key players in the immune system, differentiation,
tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Melton C, Judson RL and Blelloch R:
Opposing microRNA families regulate self-renewal in mouse embryonic
stem cells. Nature. 463:621–626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong
C, Huang Y, Hu X, Su F, Lieberman J, et al: let-7 regulates self
renewal and tumorigenicity of breast cancer cells. Cell.
131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimono Y, Zabala M, Cho RW, Lobo N,
Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al:
Downregulation of miRNA-200c links breast cancer stem cells with
normal stem cells. Cell. 138:592–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qin J, Ke J, Xu J, Wang F, Zhou Y, Jiang Y
and Wang Z: Downregulation of microRNA-132 by DNA hypermethylation
is associated with cell invasion in colorectal cancer. Onco Targets
Ther. 8:3639–3648. 2015.PubMed/NCBI
|
|
23
|
Li Y, Zu L, Wang Y, Wang M, Chen P and
Zhou Q: miR-132 inhibits lung cancer cell migration and invasion by
targeting SOX4. J Thorac Dis. 7:1563–1569. 2015.PubMed/NCBI
|
|
24
|
Lei CJ, Li L, Gao X, Zhang J, Pan QY, Long
HC, Chen CZ, Ren DF and Zheng G: Hsa-miR-132 inhibits proliferation
of hepatic carcinoma cells by targeting YAP. Cell Biochem Funct.
33:326–333. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Parker NR, Correia N, Crossley B, Buckland
ME, Howell VM and Wheeler HR: Correlation of MicroRNA 132
upregulation with an unfavorable clinical outcome in patients with
primary glioblastoma multiforme treated with radiotherapy plus
concomitant and adjuvant temozolomide chemotherapy. Transl Oncol.
6:742–748. 2013. View Article : Google Scholar
|
|
26
|
Markiewicz-Żukowska R, Borawska MH,
Fiedorowicz A, Naliwajko SK, Sawicka D and Car H: Propolis changes
the anticancer activity of temozolomide in U87MG human glioblastoma
cellline 2013. BMC Complement Altern Med. 13:502013. View Article : Google Scholar
|
|
27
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Upregulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren ZG, Dong SX, Han P and Qi J: miR-203
promotes proliferation, migration and invasion by degrading SIK1 in
pancreatic cancer. Oncol Rep. 35:1365–1374. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kohsaka S, Wang L, Yachi K, Mahabir R,
Narita T, Itoh T, Tanino M, Kimura T, Nishihara H and Tanaka S:
STAT3 inhibition overcomes temozolomide resistance in glioblastoma
by downregulating MGMT expression. Mol Cancer Ther. 11:1289–1299.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Cai S, Bailey BJ, Reza Saadatzadeh
M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long
EC, Minto RE, et al: Combination therapy in a xenograft model of
glioblastoma: Enhancement of the antitumor activity of temozolomide
by an MDM2 antagonist. J Neurosurg. 126:446–459. 2017. View Article : Google Scholar
|
|
31
|
Brescia P, Ortensi B, Fornasari L, Levi D,
Broggi G and Pelicci G: CD133 is essential for glioblastoma stem
cell maintenance. Stem Cells. 31:857–869. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Bacco F, D'Ambrosio A, Casanova E,
Orzan F, Neggia R, Albano R, Verginelli F, Cominelli M, Poliani PL,
Luraghi P, et al: MET inhibition overcomes radiation resistance of
glioblastoma stem-like cells. EMBO Mol Med. 8:550–568. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fang X, Huang Z, Zhou W, Wu Q, Sloan AE,
Ouyang G, McLendon RE, Yu JS, Rich JN and Bao S: The zinc finger
transcription factor ZFX is required for maintaining the
tumorigenic potential of glioblastoma stem cells. Stem Cells.
32:2033–2047. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoshikawa K, Noguchi K, Nakano Y, Yamamura
M, Takaoka K, Hashimoto-Tamaoki T and Kishimoto H: The Hippo
pathway transcriptional co-activator, YAP, confers resistance to
cisplatin in human oral squamous cell carcinoma. Int J Oncol.
46:2364–2370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pasquinelli AE, Reinhart BJ, Slack F,
Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B,
Müller P, et al: Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature.
408:86–89. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Magill ST, Cambronne XA, Luikart BW, Lioy
DT, Leighton BH, Westbrook GL, Mandel G and Goodman RH:
microRNA-132 regulates dendritic growth and arborization of newborn
neurons in the adult hippocampus. Proc Natl Acad Sci USA.
107:20382–20387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kawashima H, Numakawa T, Kumamaru E,
Adachi N, Mizuno H, Ninomiya M, Kunugi H and Hashido K:
Glucocorticoid attenuates brain-derived neurotrophic
factor-dependent upregulation of glutamate receptors via the
suppression of microRNA-132 expression. Neuroscience.
165:1301–1311. 2010. View Article : Google Scholar
|
|
39
|
Shaked I, Meerson A, Wolf Y, Avni R,
Greenberg D, Gilboa-Geffen A and Soreq H: MicroRNA-132 potentiates
cholinergic anti-inflammatory signaling by targeting
acetylcholinesterase. Immunity. 31:965–973. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang D, Li T, Wang Y, Tang Y, Cui H, Tang
Y, Zhang X, Chen D, Shen N and Le W: miR-132 regulates the
differentiation of dopamine neurons by directly targeting Nurr1
expression. J Cell Sci. 125:1673–1682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park
JE, Park KH, Jung KH, Lee SK, Kim M, et al: Altered microRNA
regulation in Huntington's disease models. Exp Neurol. 227:172–179.
2011. View Article : Google Scholar
|
|
42
|
Miller BH, Zeier Z, Xi L, Lanz TA, Deng S,
Strathmann J, Willoughby D, Kenny PJ, Elsworth JD, Lawrence MS, et
al: MicroRNA-132 dysregulation in schizophrenia has implications
for both neurodevelopment and adult brain function. Proc Natl Acad
Sci USA. 109:3125–3130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Alieva AKh, Filatova EV, Karabanov AV,
Illarioshkin SN, Limborska SA, Shadrina MI and Slominsky PA: miRNA
expression is highly sensitive to a drug therapy in Parkinson's
disease. Parkinsonism Relat Disord Jan. 21:72–74. 2015. View Article : Google Scholar
|
|
44
|
Diehn M and Clarke MF: Cancer stem cells
and radiotherapy: New insights into tumor radioresistance. J Natl
Cancer Inst. 98:1755–1757. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Eramo A, Ricci-Vitiani L, Zeuner A,
Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C and
De Maria R: Chemotherapy resistance of glioblastoma stem cells.
Cell Death Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gu Y, Wang Q, Guo K, Qin W, Liao W, Wang
S, Ding Y and Lin J: TUSC3 promotes colorectal cancer progression
and epithelial-mesenchymal transition (EMT) through WNT/β-catenin
and MAPK signalling. J Pathol. 239:60–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sanai N, Alvarez-Buylla A and Berger MS:
Neural stem cells and the origin of gliomas. N Engl J Med.
353:811–822. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tang H, Zhao J, Zhang L, Zhao J, Zhuang Y
and Liang P: SRPX2 enhances the epithelial-mesenchymal transition
and temozolomide resistance in glioblastoma cells. Cell Mol
Neurobiol. 36:1067–1076. 2016. View Article : Google Scholar
|
